Heron Therapeutics (HRTX) Competitors $2.16 +0.02 (+0.70%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$2.16 0.00 (0.00%) As of 07/3/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. CVAC, CALT, GPCR, AUPH, NAGE, AMPH, DYN, PAHC, BGM, and ABCLShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), BGM Group (BGM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics Phibro Animal Health BGM Group AbCellera Biologics CureVac (NASDAQ:CVAC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Does the media favor CVAC or HRTX? In the previous week, Heron Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Heron Therapeutics and 1 mentions for CureVac. Heron Therapeutics' average media sentiment score of 0.97 beat CureVac's score of -0.17 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, CVAC or HRTX? CureVac has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$579.18M2.09$175.50M$0.925.86Heron Therapeutics$148.52M2.22-$13.58M-$0.06-36.08 Is CVAC or HRTX more profitable? CureVac has a net margin of 35.44% compared to Heron Therapeutics' net margin of -5.24%. CureVac's return on equity of 30.89% beat Heron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CureVac35.44% 30.89% 25.54% Heron Therapeutics -5.24%N/A -3.43% Which has more risk & volatility, CVAC or HRTX? CureVac has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Do institutionals and insiders believe in CVAC or HRTX? 17.3% of CureVac shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate CVAC or HRTX? CureVac currently has a consensus price target of $6.83, indicating a potential upside of 26.66%. Heron Therapeutics has a consensus price target of $5.00, indicating a potential upside of 130.95%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCureVac and Heron Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$330.30M$2.41B$5.49B$9.02BDividend YieldN/A1.77%5.38%4.10%P/E Ratio-36.088.9827.4720.28Price / Sales2.22669.86408.86121.46Price / CashN/A157.0736.6357.47Price / Book-9.844.638.095.68Net Income-$13.58M$31.34M$3.17B$248.96M7 Day Performance1.17%3.25%2.81%3.30%1 Month Performance6.13%6.80%3.67%5.20%1 Year Performance-21.84%1.89%35.41%21.37% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics3.9781 of 5 stars$2.17+0.7%$5.00+130.9%-21.8%$330.30M$148.52M-36.08300News CoveragePositive NewsCVACCureVac4.6485 of 5 stars$5.43+0.9%$6.83+25.8%+72.9%$1.22B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.969 of 5 stars$20.74-1.6%$76.17+267.2%-44.9%$1.19BN/A-23.84136Positive NewsAUPHAurinia Pharmaceuticals3.2766 of 5 stars$8.47-2.0%$11.50+35.8%+38.3%$1.14B$235.13M30.25300NAGENiagen Bioscience1.527 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.14B$107.93M84.76120AMPHAmphastar Pharmaceuticals4.3608 of 5 stars$22.96-0.5%$32.33+40.8%-39.9%$1.08B$730.66M8.322,028News CoverageDYNDyne Therapeutics3.5149 of 5 stars$9.52-0.5%$41.13+332.0%-73.5%$1.08BN/A-2.65100PAHCPhibro Animal Health3.6728 of 5 stars$25.54-0.5%$21.80-14.6%+63.3%$1.04B$1.02B32.741,940BGMBGM GroupN/A$10.59-11.5%N/AN/A$1.03B$25.10M0.00298ABCLAbCellera Biologics2.5187 of 5 stars$3.43-5.0%$8.33+143.0%+40.4%$1.02B$28.83M-6.12500High Trading Volume Related Companies and Tools Related Companies CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Structure Therapeutics Competitors Aurinia Pharmaceuticals Competitors Niagen Bioscience Competitors Amphastar Pharmaceuticals Competitors Dyne Therapeutics Competitors Phibro Animal Health Competitors BGM Group Competitors AbCellera Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HRTX Stock Alerts